CELINE NIPPER: Open Payments
NPI 1649901620 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,114 in 49 payments from 12 companies in 2025. Trend: 2023 $703 · 2024 $1,202 · 2025 $1,114
Food & beverage: $1,113Travel & lodging: $1
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 19 | $347 |
| Lundbeck LLC | 9 | $260 |
| Lilly USA, LLC | 6 | $153 |
| Biogen, Inc. | 3 | $71 |
| Genentech USA, Inc. | 3 | $67 |
| Neurelis, Inc. | 2 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| ARGENX US, INC. | 1 | $33 |
| Eisai Inc. | 1 | $32 |
| GlaxoSmithKline, LLC. | 1 | $27 |
Products named: Zilbrysq, VYEPTI, KISUNLA, Briviact, LEQEMBI, Ocrevus Zunovo, VALTOCO, REXULTI.
Industry payments across CA — which companies pay providers there.
